journal
https://read.qxmd.com/read/38341557/correction-glial-cell-proteome-using-targeted-quantitative-methods-for-potential-multi-diagnostic-biomarkers
#21
Narae Kang, Hyun Jeong Oh, Ji Hye Hong, Hyo Eun Moon, Yona Kim, Hyeon-Jeong Lee, Hophil Min, Hyeonji Park, Sang Hun Lee, Sun Ha Paek, Jonghwa Jin
No abstract text is available yet for this article.
February 10, 2024: Clinical Proteomics
https://read.qxmd.com/read/38311768/absolute-quantitation-of-human-wild-type-dnai1-protein-in-lung-tissue-using-a-nanolc-prm-ms-based-targeted-proteomics-approach-coupled-with-immunoprecipitation
#22
JOURNAL ARTICLE
Hui Wang, Xiaoyan Ni, Nicholas Clark, Kristen Randall, Lianne Boeglin, Sudha Chivukula, Caroline Woo, Frank DeRosa, Gang Sun
BACKGROUND: Dynein axonemal intermediate chain 1 protein (DNAI1) plays an essential role in cilia structure and function, while its mutations lead to primary ciliary dyskinesia (PCD). Accurate quantitation of DNAI1 in lung tissue is crucial for comprehensive understanding of its involvement in PCD, as well as for developing the potential PCD therapies. However, the current protein quantitation method is not sensitive enough to detect the endogenous level of DNAI1 in complex biological matrix such as lung tissue...
February 4, 2024: Clinical Proteomics
https://read.qxmd.com/read/38291365/frozen-tissue-coring-and-layered-histological-analysis-improves-cell-type-specific-proteogenomic-characterization-of-pancreatic-adenocarcinoma
#23
JOURNAL ARTICLE
Sara R Savage, Yuefan Wang, Lijun Chen, Scott Jewell, Chelsea Newton, Yongchao Dou, Qing Kay Li, Oliver F Bathe, Ana I Robles, Gilbert S Omenn, Mathangi Thiagarajan, Hui Zhang, Galen Hostetter, Bing Zhang
BACKGROUND: Omics characterization of pancreatic adenocarcinoma tissue is complicated by the highly heterogeneous and mixed populations of cells. We evaluate the feasibility and potential benefit of using a coring method to enrich specific regions from bulk tissue and then perform proteogenomic analyses. METHODS: We used the Biopsy Trifecta Extraction (BioTExt) technique to isolate cores of epithelial-enriched and stroma-enriched tissue from pancreatic tumor and adjacent tissue blocks...
January 30, 2024: Clinical Proteomics
https://read.qxmd.com/read/38287260/recent-developments-in-mass-spectrometry-based-targeted-proteomics-of-clinical-cancer-biomarkers
#24
REVIEW
Deborah Wenk, Charlotte Zuo, Thomas Kislinger, Lusia Sepiashvili
Routine measurement of cancer biomarkers is performed for early detection, risk classification, and treatment monitoring, among other applications, and has substantially contributed to better clinical outcomes for patients. However, there remains an unmet need for clinically validated assays of cancer protein biomarkers. Protein tumor markers are of particular interest since proteins carry out the majority of biological processes and thus dynamically reflect changes in cancer pathophysiology. Mass spectrometry-based targeted proteomics is a powerful tool for absolute peptide and protein quantification in biological matrices with numerous advantages that make it attractive for clinical applications in oncology...
January 30, 2024: Clinical Proteomics
https://read.qxmd.com/read/38267848/an-lc-ms-based-designated-comparison-method-with-similar-performance-to-the-lp-a-reference-measurement-procedure-to-guide-molar-lp-a-standardization
#25
JOURNAL ARTICLE
Nina M Diederiks, L Renee Ruhaak, Fred P H T M Romijn, Mervin M Pieterse, Nico P M Smit, Christa M Cobbaert
BACKGROUND: The 2022 consensus statement of the European Atherosclerosis Society (EAS) on lipoprotein(a) (Lp(a)) recognizes the role of Lp(a) as a relevant genetically determined risk factor and recommends its measurement at least once in an individual's lifetime. It also strongly urges that Lp(a) test results are expressed as apolipoprotein (a) (apo(a)) amount of substance in molar units and no longer in confounded Lp(a) mass units (mg/dL or mg/L). Therefore, IVD manufacturers should transition to molar units...
January 24, 2024: Clinical Proteomics
https://read.qxmd.com/read/38254014/mapping-three-dimensional-intratumor-proteomic-heterogeneity-in-uterine-serous-carcinoma-by-multiregion-microsampling
#26
JOURNAL ARTICLE
Allison L Hunt, Nicholas W Bateman, Waleed Barakat, Sasha C Makohon-Moore, Tamara Abulez, Jordan A Driscoll, Joshua P Schaaf, Brian L Hood, Kelly A Conrads, Ming Zhou, Valerie Calvert, Mariaelena Pierobon, Jeremy Loffredo, Katlin N Wilson, Tracy J Litzi, Pang-Ning Teng, Julie Oliver, Dave Mitchell, Glenn Gist, Christine Rojas, Brian Blanton, Kathleen M Darcy, Uma N M Rao, Emanuel F Petricoin, Neil T Phippen, G Larry Maxwell, Thomas P Conrads
BACKGROUND: Although uterine serous carcinoma (USC) represents a small proportion of all uterine cancer cases, patients with this aggressive subtype typically have high rates of chemotherapy resistance and disease recurrence that collectively result in a disproportionately high death rate. The goal of this study was to provide a deeper view of the tumor microenvironment of this poorly characterized uterine cancer variant through multi-region microsampling and quantitative proteomics. METHODS: Tumor epithelium, tumor-involved stroma, and whole "bulk" tissue were harvested by laser microdissection (LMD) from spatially resolved levels from nine USC patient tumor specimens and underwent proteomic analysis by mass spectrometry and reverse phase protein arrays, as well as transcriptomic analysis by RNA-sequencing for one patient's tumor...
January 22, 2024: Clinical Proteomics
https://read.qxmd.com/read/38225548/kinase-inhibitor-pulldown-assay-kip-for-clinical-proteomics
#27
JOURNAL ARTICLE
Alexander B Saltzman, Doug W Chan, Matthew V Holt, Junkai Wang, Eric J Jaehnig, Meenakshi Anurag, Purba Singh, Anna Malovannaya, Beom-Jun Kim, Matthew J Ellis
Protein kinases are frequently dysregulated and/or mutated in cancer and represent essential targets for therapy. Accurate quantification is essential. For breast cancer treatment, the identification and quantification of the protein kinase ERBB2 is critical for therapeutic decisions. While immunohistochemistry (IHC) is the current clinical diagnostic approach, it is only semiquantitative. Mass spectrometry-based proteomics offers quantitative assays that, unlike IHC, can be used to accurately evaluate hundreds of kinases simultaneously...
January 16, 2024: Clinical Proteomics
https://read.qxmd.com/read/38182978/prognostic-biomarker-discovery-based-on-proteome-landscape-of-chinese-lung-adenocarcinoma
#28
JOURNAL ARTICLE
Yuqi Huang, Sheng Ma, Jun-Yu Xu, Kun Qian, Yaru Wang, Yi Zhang, Minjia Tan, Ting Xiao
Despite recent innovations in imaging and genomic screening promotes advance in diagnosis and treatment of lung adenocarcinoma (LUAD), there remains high mortality of LUAD and insufficient understanding of LUAD biology. Our previous study performed an integrative multi-omic analysis of LUAD, filling the gap between genomic alterations and their biological proteome effects. However, more detailed molecular characterization and biomarker resources at proteome level still need to be uncovered. In this study, a quantitative proteomic experiment of patient-derived benign lung disease samples was carried out...
January 5, 2024: Clinical Proteomics
https://read.qxmd.com/read/38172678/quantification-of-putative-ovarian-cancer-serum-protein-biomarkers-using-a-multiplexed-targeted-mass-spectrometry-assay
#29
JOURNAL ARTICLE
Joohyun Ryu, Kristin L M Boylan, Carly A I Twigg, Richard Evans, Amy P N Skubitz, Stefani N Thomas
BACKGROUND: Ovarian cancer is the most lethal gynecologic malignancy in women, and high-grade serous ovarian cancer (HGSOC) is the most common subtype. Currently, no clinical test has been approved by the FDA to screen the general population for ovarian cancer. This underscores the critical need for the development of a robust methodology combined with novel technology to detect diagnostic biomarkers for HGSOC in the sera of women. Targeted mass spectrometry (MS) can be used to identify and quantify specific peptides/proteins in complex biological samples with high accuracy, sensitivity, and reproducibility...
January 3, 2024: Clinical Proteomics
https://read.qxmd.com/read/38053024/sbiosite-enables-sensitive-identification-of-the-cell-surface-proteome-through-direct-enrichment-of-biotinylated-peptides
#30
JOURNAL ARTICLE
Kishore Garapati, Husheng Ding, M Cristine Charlesworth, Yohan Kim, Roman Zenka, Mayank Saraswat, Dong-Gi Mun, Sandip Chavan, Ashish Shingade, Fabrice Lucien, Jun Zhong, Richard K Kandasamy, Akhilesh Pandey
BACKGROUND: Cell surface proteins perform critical functions related to immune response, signal transduction, cell-cell interactions, and cell migration. Expression of specific cell surface proteins can determine cell-type identity, and can be altered in diseases including infections, cancer and genetic disorders. Identification of the cell surface proteome remains a challenge despite several enrichment methods exploiting their biochemical and biophysical properties. METHODS: Here, we report a novel method for enrichment of proteins localized to cell surface...
December 5, 2023: Clinical Proteomics
https://read.qxmd.com/read/38036981/quantitative-proteomics-analysis-based-on-data-independent-acquisition-reveals-the-effect-of-shenling-baizhu-powder-slp-on-protein-expression-in-mafld-rat-liver-tissue
#31
JOURNAL ARTICLE
Sufei Song, Jixian Zheng, Dongmei Zhao, Anni Zheng, Ye Zhu, Qiuling Xu, Tao Liu
BACKGROUND: Metabolic associated fatty liver disease (MAFLD) has become the most common chronic liver disease worldwide, and it is also a high-risk factor for the development of other metabolic diseases. Shenling Baizhu powder (SLP) is a traditional Chinese herbal formula with good clinical efficacy against MAFLD. However, its molecular mechanism for the treatment of MAFLD is still not fully understood. This study used quantitative proteomics analysis to reveal the SLP action mechanism in the treatment of MAFLD by discovering the effect of SLP on protein expression in the liver tissue of MAFLD rats...
December 1, 2023: Clinical Proteomics
https://read.qxmd.com/read/38017436/validation-of-the-novel-glas-algorithm-as-an-aid-in-the-detection-of-liver-fibrosis-and-cirrhosis-based-on-gp73-lg2m-age-and-sex
#32
JOURNAL ARTICLE
Philip M Hemken, Xuzhen Qin, Lori J Sokoll, Laurel Jackson, Fan Feng, Peng Li, Susan H Gawel, Bailin Tu, Zhihong Lin, James Hartnett, David Hawksworth, Bryan C Tieman, Toru Yoshimura, Hideki Kinukawa, Shaohua Ning, Enfu Liu, Fanju Meng, Fei Chen, Juru Miao, Xuan Mi, Xin Tong, Daniel W Chan, Gerard J Davis
BACKGROUND: Diagnosis of liver disease at earlier stages can improve outcomes and reduce the risk of progression to malignancy. Liver biopsy is the gold standard for diagnosis of liver disease, but is invasive and sample acquisition errors are common. Serum biomarkers for liver function and fibrosis, combined with patient factors, may allow for noninvasive detection of liver disease. In this pilot study, we tested and validated the performance of an algorithm that combines GP73 and LG2m serum biomarkers with age and sex (GLAS) to differentiate between patients with liver disease and healthy individuals in two independent cohorts...
November 28, 2023: Clinical Proteomics
https://read.qxmd.com/read/38017382/proteomic-analysis-of-chromophobe-renal-cell-carcinoma-and-benign-renal-oncocytoma-biopsies-reveals-shared-metabolic-dysregulation
#33
JOURNAL ARTICLE
Luis B Carvalho, Susana Jorge, Hugo López-Fernández, Carlos Lodeiro, Rajiv Dhir, Luis Campos Pinheiro, Mariana Medeiros, Hugo M Santos, José L Capelo
BACKGROUND: This study investigates the proteomic landscapes of chromophobe renal cell carcinoma (chRCC) and renal oncocytomas (RO), two subtypes of renal cell carcinoma that together account for approximately 10% of all renal tumors. Despite their histological similarities and shared origins, chRCC is a malignant tumor necessitating aggressive intervention, while RO, a benign growth, is often subject to overtreatment due to difficulties in accurate differentiation. METHODS: We conducted a label-free quantitative proteomic analysis on solid biopsies of chRCC (n = 5), RO (n = 5), and normal adjacent tissue (NAT, n = 5)...
November 28, 2023: Clinical Proteomics
https://read.qxmd.com/read/37990292/development-of-a-predictive-model-to-distinguish-prostate-cancer-from-benign-prostatic-hyperplasia-by-integrating-serum-glycoproteomics-and-clinical-variables
#34
JOURNAL ARTICLE
Caterina Gabriele, Federica Aracri, Licia Elvira Prestagiacomo, Maria Antonietta Rota, Stefano Alba, Giuseppe Tradigo, Pietro Hiram Guzzi, Giovanni Cuda, Rocco Damiano, Pierangelo Veltri, Marco Gaspari
BACKGROUND: Prostate Cancer (PCa) represents the second leading cause of cancer-related death in men. Prostate-specific antigen (PSA) serum testing, currently used for PCa screening, lacks the necessary sensitivity and specificity. New non-invasive diagnostic tools able to discriminate tumoral from benign conditions and aggressive (AG-PCa) from indolent forms of PCa (NAG-PCa) are required to avoid unnecessary biopsies. METHODS: In this work, 32 formerly N-glycosylated peptides were quantified by PRM (parallel reaction monitoring) in 163 serum samples (79 from PCa patients and 84 from individuals affected by benign prostatic hyperplasia (BPH)) in two technical replicates...
November 21, 2023: Clinical Proteomics
https://read.qxmd.com/read/37968584/comparison-of-in-gel-and-in-solution-proteolysis-in-the-proteome-profiling-of-organ-perfusion-solutions
#35
JOURNAL ARTICLE
Corinna M Snashall, Chris W Sutton, Letizia Lo Faro, Carlo Ceresa, Rutger Ploeg, Sadr Ul Shaheed
PURPOSE: The organ perfusion solution (perfusate), collected at clinically and temporally significant stages of the organ preservation and transplantation process, provides a valuable insight into the biological status of an organ over time and prior to reperfusion (transplantation) in the recipient. The objective of this study was to assess two bottom-up proteomics workflows for the extraction of tryptic peptides from the perfusate. EXPERIMENTAL DESIGN: Two different kinds of perfusate samples from kidney and liver trials were profiled using liquid chromatography-mass spectrometry (LC-MS/MS)...
November 15, 2023: Clinical Proteomics
https://read.qxmd.com/read/37950160/a-pathway-activity-based-proteomic-classifier-stratifies-prostate-tumors-into-two-subtypes
#36
JOURNAL ARTICLE
Rui Sun, Lingling Tan, Xuan Ding, Jun A, Zhangzhi Xue, Xue Cai, Sainan Li, Tiannan Guo
Prostate cancer (PCa) is the second most common cancer in males worldwide. The risk stratification of PCa is mainly based on morphological examination. Here we analyzed the proteome of 667 tumor samples from 487 Chinese PCa patients and characterized 9576 protein groups by PulseDIA mass spectrometry. Then we developed a pathway activity-based classifier concerning 13 proteins from seven pathways, and dichotomized the PCa patients into two subtypes, namely PPS1 and PPS2. PPS1 is featured with enhanced innate immunity, while PPS2 with suppressed innate immunity...
November 11, 2023: Clinical Proteomics
https://read.qxmd.com/read/37940875/candidate-biomarkers-for-treatment-benefit-from-sunitinib-in-patients-with-advanced-renal-cell-carcinoma-using-mass-spectrometry-based-phospho-proteomics
#37
JOURNAL ARTICLE
Hanneke van der Wijngaart, Robin Beekhof, Jaco C Knol, Alex A Henneman, Richard de Goeij-de Haas, Sander R Piersma, Thang V Pham, Connie R Jimenez, Henk M W Verheul, Mariette Labots
The tyrosine kinase inhibitor sunitinib is an effective first-line treatment for patients with advanced renal cell carcinoma (RCC). Hypothesizing that a functional read-out by mass spectrometry-based (phospho, p-)proteomics will identify predictive biomarkers for treatment outcome of sunitinib, tumor tissues of 26 RCC patients were analyzed. Eight patients had primary resistant (RES) and 18 sensitive (SENS) RCC. A 78 phosphosite signature (p < 0.05, fold-change > 2) was identified; 22 p-sites were upregulated in RES (unique in RES: BCAR3, NOP58, EIF4A2, GDI1) and 56 in SENS (35 unique)...
November 8, 2023: Clinical Proteomics
https://read.qxmd.com/read/37880622/mass-spectrometry-quantifies-target-engagement-for-a-krasg12c-inhibitor-in-ffpe-tumor-tissue
#38
JOURNAL ARTICLE
Andrew G Chambers, David C Chain, Steve M Sweet, Zifeng Song, Philip L Martin, Matthew J Ellis, Claire Rooney, Yeoun Jin Kim
BACKGROUND: Quantification of drug-target binding is critical for confirming that drugs reach their intended protein targets, understanding the mechanism of action, and interpreting dose-response relationships. For covalent inhibitors, target engagement can be inferred by free target levels before and after treatment. Targeted mass spectrometry assays offer precise protein quantification in complex biological samples and have been routinely applied in pre-clinical studies to quantify target engagement in frozen tumor tissues for oncology drug development...
October 25, 2023: Clinical Proteomics
https://read.qxmd.com/read/37880620/change-of-histone-h3-lysine-14-acetylation-stoichiometry-in-human-monocyte-derived-macrophages-as-determined-by-ms-based-absolute-targeted-quantitative-proteomic-approach-hiv-infection-and-methamphetamine-exposure
#39
JOURNAL ARTICLE
Katarzyna Macur, Andrew Schissel, Fang Yu, Shulei Lei, Brenda Morsey, Howard S Fox, Pawel Ciborowski
BACKGROUND: Histones posttranslational modification represent an epigenetic mechanism that regulate gene expression and other cellular processes. Quantitative mass spectrometry used for the absolute quantification of such modifications provides further insight into cellular responses to extracellular insults such as infections or toxins. Methamphetamine (Meth), a drug of abuse, is affecting the overall function of the immune system. In this report, we developed, validated and applied a targeted, MS-based quantification assay to measure changes in histone H3 lysine 14 acetylation (H3K14Ac) during exposure of human primary macrophages to HIV-1 infection and/or Meth...
October 25, 2023: Clinical Proteomics
https://read.qxmd.com/read/37880604/comment-on-cerebrospinal-fluid-camk2a-levels-at-baseline-predict-long-term-progression-in-multiple-sclerosis-clinical-proteomics
#40
LETTER
Fereshteh Behdarvand Dehkordi, Mohammad Chehelgerdi
No abstract text is available yet for this article.
October 25, 2023: Clinical Proteomics
journal
journal
40491
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.